ADM licenses first product in microbiome-targeted tie-up with Gnubiotics

By Jane Byrne

- Last updated on GMT

© GettyImages/Image Source
© GettyImages/Image Source

Related tags Adm cats dogs Gnubiotics

ADM has licensed a glycopeptides-based product from Gnubiotics, a Swiss biotech company.

AMOBIOME is the first ingredient to be commercialized since the two companies entered a strategic partnership in 2022. ADM is set to use the product in formulations for supplements and pet food across its global supply chain.

The product is an oligosaccharides-peptides complex and when used as a source of amino acids, peptides, and glycopeptides in food for cats and dogs the inclusion level should not exceed 1.5% by weight in complete food.  

Scientists at Gnubiotics investigated the effect of the milk oligosaccharide (MO) biosimilar on the gut microbiome composition and recently published data suggesting AMOBIOME may provide microbiome stability during disturbance by an antibiotic.

FDA communication 

“The product is exciting as it shows the ability to reduce the negative effect of antibiotics on the microbiome and it is the first product of its kind to get an FDA GRAS no questions letter,” Yemi Adesokan, CEO of Gnubiotics, told us.

The company received that letter​ from the US Food and Drug Administration (FDA) in December last year in relation to AMOBIOME's inclusion in food for cats and dogs.

“A ‘no questions’ letter provides an additional level of regulatory acceptance as we continue to prioritize safety and transparency for AMOBIOME,” reported Adesokan.

The substance is produced from protein hydrolysate of porcine intestinal mucosa, according to the data included in the FDA communication.

Any potential viruses are inactivated, noted the letter. The raw materials used are regulated as feeding materials in other jurisdictions such as the EU and Canada.

Related topics Suppliers

Related news

Show more